Subscribe
Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships.
Predictions: ADC, Single-Use Technologies, Regulatory Transparency
Catalent Biologics Expands Into ADCs
Astellas and Ambrx Collaborate on Antibody Drug Conjugates for Oncology